[A case of effective use of alemtuzumab in a male patient with T-cell lymphoma].
Sokolov
A H
AH
Parovichnikova
E N
EN
Isaev
V G
VG
Ustinova
E N
EN
Shavlokhov
V S
VS
Atopkov
V A
VA
Model
S V
SV
Tsyba
N N
NN
Kaplanskaia
I B
IB
Kliasova
G A
GA
Aleksanian
M Zh
MZh
Vishnevskaia
E S
ES
Togonidze
D K
DK
Mirzoian
E E
EE
Savchenko
V G
VG
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D013156:Splenectomy; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone